A Multicenter Randomized, Double-blind, Parallel, Positive-controlled Phase III Clinical Trial to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria
Latest Information Update: 06 Jun 2023
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma; Asthma; Urticaria
- Focus Therapeutic Use
- Sponsors CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Most Recent Events
- 22 Jun 2021 Status changed from planning to not yet recruiting.
- 20 Apr 2020 New trial record
- 19 Apr 2020 According to a CSPC Pharmaceutical Group media release, application for phase III clinical trial in China is expected to be submitted in the near term.